The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care.
During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts will discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap. This lunch symposium, brought to you by Medical Learning Institute, Inc. (MLI), will be certified for continuing education credit for physicians, nurses, and pharmacists and will offer American Board of Internal Medicine Maintenance of Certification points. Don’t miss this exciting lunch symposium— REGISTER TODAY to reserve your spot!
This CE activity is intended for hematologic oncology clinicians, nurses, and pharmacists who provide care for individuals with mantle cell lymphoma (MCL).
After completing this CE activity, the participant should be better able to:
- Develop strategies to utilize prognostic tools to improve care for patients with MCL with genomic alterations
- Plan strategies to integrate emerging efficacy and safety data for approved and novel frontline treatment regimens to improve outcomes for patients with MCL
- Formulate plans to integrate emerging efficacy and safety data for treatment regimens recommended in the guidelines and by experts to enhance outcomes for patients with R/R MCL
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME(R)) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC(R)) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-067-L01-P
Type of Activity: Knowledge
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.
Copyright © 2022 Medical Learning Institute, Inc. | All Rights Reserved.
|Welcome, introductions, overview||5 minutes|
|Using prognostic tools to plan treatment for individuals with MCL and targetable mutations; case vignette*||10 minutes|
|Integrating emerging data and guidelines recommendations for front-line treatment; benefits and risks of chemotherapy-free targeted options for treatment outcomes; case vignette*||17 minutes|
|Planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL; case vignette*||18 minutes|
|Summary of key points, post-test, evaluation, and final Q&A||10 minutes|
*Please note each topic includes a 5 min Q&A
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Jia Ruan, MD, PhD
Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY
LOCATION & TIME
1600 Lamar, Houston, TX 77010
Level 4, Grand Ballroom ABC
11:32 am – 12:32 pm CDT
This CE activity is supported by educational grants from AstraZeneca, Pharmacyclics, LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.